Medical 21, Inc. Announces Regulatory Approval to Initiate First-in-Human Clinical Study in Spain
Source: Yahoo FinanceRegulatory clearance enables launch of the MAVERICS Coronary Revascularization Study, advancing evaluation of the Company's next-generation synthetic small-diameter bypass graft.
MINNEAPOLIS, Dec. 15, 2025 /PRNewswire/ -- Medical 21, Inc., a private medical technology company developing a novel regenerative small-diameter coronary bypass graft, today announced that it has received regulatory approval in Spain under the European Union Medical Device Regulation (EU MDR) to initiate the Company's first-in-human, multicenter clinical trial of the MAVERICS graft, the MAVERICS Coronary Revascularization Study.
